JP2023550310A - 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト - Google Patents

虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト Download PDF

Info

Publication number
JP2023550310A
JP2023550310A JP2023528093A JP2023528093A JP2023550310A JP 2023550310 A JP2023550310 A JP 2023550310A JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023550310 A JP2023550310 A JP 2023550310A
Authority
JP
Japan
Prior art keywords
vista
agonist
antibody
optionally
iri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550310A5 (https=
Inventor
ジェイ ノエル，ランドルフ
スミッツ，ニコール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dartmouth College
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of JP2023550310A publication Critical patent/JP2023550310A/ja
Publication of JP2023550310A5 publication Critical patent/JP2023550310A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2023528093A 2020-11-04 2021-11-04 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト Pending JP2023550310A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063109584P 2020-11-04 2020-11-04
US63/109,584 2020-11-04
PCT/US2021/058020 WO2022098846A1 (en) 2020-11-04 2021-11-04 Vista agonist for treatment/prevention of ischemic and/or reperfusion injury

Publications (2)

Publication Number Publication Date
JP2023550310A true JP2023550310A (ja) 2023-12-01
JP2023550310A5 JP2023550310A5 (https=) 2024-11-07

Family

ID=81458372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528093A Pending JP2023550310A (ja) 2020-11-04 2021-11-04 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト

Country Status (8)

Country Link
US (1) US20230399405A1 (https=)
EP (1) EP4240409A4 (https=)
JP (1) JP2023550310A (https=)
KR (1) KR20230142828A (https=)
CN (1) CN116600826A (https=)
AU (1) AU2021373781A1 (https=)
CA (1) CA3197359A1 (https=)
WO (1) WO2022098846A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172543A1 (ko) * 2023-02-17 2024-08-22 뉴패스바이오(주) Igsf11-fc 융합 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 자가면역질환 또는 염증성 질환의 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525943A (ja) * 2016-04-15 2019-09-12 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6285923B2 (ja) * 2012-06-22 2018-02-28 トラスティーズ・オブ・ダートマス・カレッジ 新規ＶＩＳＴＡ−Ｉｇコンストラクト及び自己免疫、アレルギー性及び炎症性障害の処置のためのＶＩＳＴＡ−Ｉｇの使用
US9381244B2 (en) * 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
BR112015013431A2 (pt) * 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
WO2017181109A1 (en) * 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525943A (ja) * 2016-04-15 2019-09-12 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIDNEY INTERNATIONAL, vol. 97, JPN6025043829, 17 December 2019 (2019-12-17), pages 980 - 994, ISSN: 0005717861 *

Also Published As

Publication number Publication date
KR20230142828A (ko) 2023-10-11
EP4240409A1 (en) 2023-09-13
CN116600826A (zh) 2023-08-15
EP4240409A4 (en) 2024-09-18
US20230399405A1 (en) 2023-12-14
CA3197359A1 (en) 2022-05-12
WO2022098846A1 (en) 2022-05-12
AU2021373781A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US20250236669A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
US20230250176A1 (en) Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
JP7045327B2 (ja) 抗血液樹状細胞抗原２抗体の臨床使用のための医薬組成物及び投与レジメン
JP2022512722A (ja) 抗ｃｄ３８抗体の皮下投与を提供する方法
US20230159634A1 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
CN121729428A (zh) α4β7整联蛋白抗体组合物和使用方法
JP2023550310A (ja) 虚血及び／または再灌流障害の治療／予防のためのｖｉｓｔａアゴニスト
WO2023098785A1 (zh) 抗4-1bb抗体及其用途
EP4341291A1 (en) Dosing regimens for protein therapeutics
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
JP2023515480A (ja) 抗ｉｌ－２抗体、その抗原結合断片及びその医薬用途
CN117279954A (zh) 抗人cxcr5抗体及其用途
US20260102490A1 (en) Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
CA3246509A1 (en) ANTI-ILT4 COMPOSITIONS AND METHODS
TW202608482A (zh) 用於治療多發性骨髓瘤之方法
EA050839B1 (ru) Способы лечения множественной миеломы
BR112016022381B1 (pt) Anticorpo humanizado isolado ou fragmento de ligação ao antígeno deste que se liga ao receptor canabinóide 1 (cb1), uso do mesmo, composição farmacêutica e método in vitro de agonizar ou antagonizar cb1
HK1233659B (en) Antibodies that bind human cannabinoid 1 (cb1) receptor
HK1233659A1 (en) Antibodies that bind human cannabinoid 1 (cb1) receptor

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241029

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260421